Phytochemical basis, multitarget pharmacology, and translational perspectives of silymarin: emphasis on its antifibrotic effects
- 1epartment of Otolaryngology, Jingjiang People’s Hospital Affiliated to Yangzhou University, Jingjiang, Jiangsu, China
Abstract
This review critically evaluates the antifibrotic potential of silymarin by integrating its phytochemical composition, formulation-dependent exposure, molecular pharmacology, cross-organ preclinical evidence, and clinical translation, while distinguishing multicomponent silymarin extracts from purified silybin/silibinin and delivery-enhanced preparations. A structured, non-systematic evidence-mapping search of PubMed/MEDLINE, Web of Science, and Scopus covered English-language literature through December 2025. A targeted update of PubMed/MEDLINE and publisher records was performed through 9 August 2026, focusing on fibrosis, pharmacokinetics, formulation, drug delivery, ferroptosis, succinate metabolism, ANXA6, and related mechanisms. Preclinical studies indicate that silymarin-related interventions can modulate TGF-β/Smad signaling, oxidative and inflammatory pathways, fibroblast activation, myofibroblast differentiation, and extracellular-matrix turnover. Recent work has added hepatocyte succinate handling, FTH1-related ferroptosis, and ANXA6-associated stress signaling. Antifibrotic activity has been reported in liver, kidney, lung, peritoneal, and skin models, whereas human evidence remains limited and heterogeneous. Product composition, oral exposure, formulation, and endpoint selection may contribute to discordant clinical findings. Silymarin has biologically plausible multitarget antifibrotic activity, but current evidence does not establish it as an antifibrotic therapy. Future studies should use chemically defined preparations, exposure-informed dosing, validated target engagement, and fibrosis-centered outcomes.
Related
- Cannabinoids in oncology: pharmacology, clinical applications, and translational perspectives
- Unraveling the multitarget mechanisms of aloe emodin against periodontitis: a synergy of network pharmacology and experimental validation
- Cardiac Fibrosis as a Dynamic Therapeutic Target: Overcoming Translational Barriers to Antifibrotic Therapy.
- Curcumin pharmacology and pharmacokinetics: current challenges and future perspectives in nanoemulsion delivery
- Ensemble signal detection reveals target-specific temporal risk of hypokalemia after immune checkpoint inhibition: a translational pharmacology framework
BibTeX
@article{jin2026phytochemical,
title = {{Phytochemical basis, multitarget pharmacology, and translational perspectives of silymarin: emphasis on its antifibrotic effects}},
author = {Zhe Jin and Jing Zhu and Binghong Lu and Yabo Li and Yan Chen},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.2001949},
url = {https://doi.org/10.3389/fphar.2026.2001949},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Phytochemical basis, multitarget pharmacology, and translational perspectives of silymarin: emphasis on its antifibrotic effects
AU - Zhe Jin
AU - Jing Zhu
AU - Binghong Lu
AU - Yabo Li
AU - Yan Chen
PY - 2026
DA - 2026/10/23
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.2001949
UR - https://doi.org/10.3389/fphar.2026.2001949
AB - This review critically evaluates the antifibrotic potential of silymarin by integrating its phytochemical composition, formulation-dependent exposure, molecular pharmacology, cross-organ preclinical evidence, and clinical translation, while distinguishing multicomponent silymarin extracts from purified silybin/silibinin and delivery-enhanced preparations. A structured, non-systematic evidence-mapping search of PubMed/MEDLINE, Web of Science, and Scopus covered English-language literature through December 2025. A targeted update of PubMed/MEDLINE and publisher records was performed through 9 August 2026, focusing on fibrosis, pharmacokinetics, formulation, drug delivery, ferroptosis, succinate metabolism, ANXA6, and related mechanisms. Preclinical studies indicate that silymarin-related interventions can modulate TGF-β/Smad signaling, oxidative and inflammatory pathways, fibroblast activation, myofibroblast differentiation, and extracellular-matrix turnover. Recent work has added hepatocyte succinate handling, FTH1-related ferroptosis, and ANXA6-associated stress signaling. Antifibrotic activity has been reported in liver, kidney, lung, peritoneal, and skin models, whereas human evidence remains limited and heterogeneous. Product composition, oral exposure, formulation, and endpoint selection may contribute to discordant clinical findings. Silymarin has biologically plausible multitarget antifibrotic activity, but current evidence does not establish it as an antifibrotic therapy. Future studies should use chemically defined preparations, exposure-informed dosing, validated target engagement, and fibrosis-centered outcomes.
SN - 1663-9812
ER -